AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9432523
Drug: Methylphenidate (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.3 mg/kg morning dose)
Trial: 9432523
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs (AEDs) only
Trial: 8260309
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion (CSCI) of morphine 30 micrograms kg‐1 h‐1 after a bolus of 0.1 mg kg‐1 i.v. at the end of the operation
Trial: 30827716
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) on postoperative day 0 (POD 0)
Trial: 30827716
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) on postoperative day 1 (POD 1)
Trial: 21457353
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AB chips and OM
Trial: 2433195
Drug: No hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormone therapy (control group)
Trial: 18562790
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (152 mg vitamin C/day and 50 mg vitamin E/day)
Trial: 12469707
Drug: Various doses
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various doses of estrogen (0.3 mg CEE, 0.25 mg 17beta‐estradiol, transdermal patches delivering 20 microg 17beta‐estradiol, intranasal methods delivering 100-400 microg 17beta‐estradiol, 0.625 mg CEE, 0.5 mg 17beta‐estradiol) with or without progestogen.
Trial: 12469707
Drug: Progestogen addition
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestogen addition to estrogen therapy in women with intact uterus.
Trial: 8460344
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) vaccination of recombinant HB vaccine
Trial: 8460344
Drug: IM booster
RxNorm normalized name: SAGE OIL 4.3 mg in 50 mL / EUCALYPTOL 13 mg in 50 mL TOPICAL OIL [Slim Booster with natural slimming activators]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM booster dose given 10 months after the third injection
Trial: 3895410
Drug: Emepronium carrageenate
RxNorm normalized name: emepronium carrageenate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emepronium carrageenate (EC) 1000 mg
Trial: 21783298
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of tramadol IM
Trial: 20738456
Drug: 0.05% chlorhexidine/herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% chlorhexidine/herbal extract combination
Trial: 1104246
Drug: 0.1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% chlorhexidine solution
Trial: 16953808
Drug: Depression screening
RxNorm normalized name: Nerve depressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depression screening and treatment
Trial: 14971519
Drug: Intradermal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccination at a dose of 0.1 ml, 2 microg, administered at 5 positions, 4 vaccinations at months 0, 1, 2, and 6 (M0, M1, M2, M6)
Trial: 14971519
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination at a dose of 1.0 ml, 20 microg, administered at 2 positions, 4 vaccinations at months 0, 1, 2, and 6 (M0, M1, M2, M6)
Trial: 22337211
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (education, muscle stretching, exercises, homework for nine treatments in 6 weeks)
Trial: 22184305
Drug: Cefazolin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (2 g) administered before skin incision
Trial: 17971285
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg daily for 6 months
Trial: 8912780
Drug: Inhaled methacholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled methacholine (intervention)
Trial: 17132970
Drug: Memantine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (20 mg per day)
Trial: 11154169
Drug: Lansoprazole or
RxNorm normalized name: lansoprazole Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole or Omeprazole with antibiotics
Trial: 9323749
Drug: Assertive community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive community treatment
Trial: 8403909
Drug: NORPLANT II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NORPLANT II contraceptive implant
Trial: 3520426
Drug: Monthly maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly maintenance therapy
Trial: 19081527
Drug: Infliximab induction
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab induction (5 mg/kg/dose) at weeks 0, 2, and 6; maintenance therapy every 8 or 12 weeks
Trial: 16093871
Drug: Pantoprazole 20
RxNorm normalized name: pantoprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 20 mg on demand for 6 months
Trial: 11870412
Drug: Cacit D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cacit D3 (1000 mg Ca and 880 IU vitamin D) taken as a single morning dose
Trial: 11870412
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no drug intake)
Trial: 7584524
Drug: Moxonidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (0.3 mg)
Trial: 7011226
Drug: Aspirin (1,300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1,300 mg daily) and dipyridamole (100 mg daily)
Trial: 30736832
Drug: Aerobic-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic-based exercise intervention (thrice-weekly, moderate-intensity aerobic exercise supplemented with isometric resistance exercise)
Trial: 30953791
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training (IMT) at 50% maximum inspiratory pressure (MIP) for 4 weeks, 30 breaths twice daily
Trial: 30953791
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (15% MIP for 4 weeks, 30 breaths twice daily)
Trial: 25307931
Drug: Ustekinumab (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (with dosing adjustments)
Trial: 31769212
Drug: Ustekinumab (overall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (overall treatment)
Trial: 21898590
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg subcutaneously every 6 months for 3 years)
Trial: 12458383
Drug: Glucomannan +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucomannan + rifaximin (400 mg twice daily for 7 days every month)
Trial: 11148445
Drug: Oral mesalazine
RxNorm normalized name: mesalamine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mesalazine 4 g
Trial: 11148445
Drug: Combined mesalazine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined mesalazine 2 g orally plus 2 g rectally as a liquid enema
Trial: 10648334
Drug: Acetaminophen 20
RxNorm normalized name: acetaminophen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 20 mg/kg (AS)
Trial: 10648334
Drug: Acetaminophen 40
RxNorm normalized name: acetaminophen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 40 mg/kg (AL)
Trial: 12850
Drug: Atenolol 300
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 300 mg/day
Trial: 776350
Drug: Methyldopa 750
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa 750 mg/day
Trial: 12850
Drug: Methyldopa 1500
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa 1500 mg/day
Trial: 12850
Drug: Atenolol 150
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 150 mg/day and Methyldopa 750 mg/day (combined treatment)
Trial: 12850
Drug: Methyldopa (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (lower dose)
Trial: 28778047
Drug: Metformin in
RxNorm normalized name: Product containing metformin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin in rats
Trial: 15948237
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg/d for 6 months (group 1 and group 2)
Trial: 15948237
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg/d for 12 months (group 1 and group 2)
Trial: 15948237
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment, group 3 and group 4)
Trial: 1569240
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ketorolac
Trial: 2676649
Drug: Doleron (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doleron (two tablets: 150 mg dextropropoxyphene napsylate, 350 mg aspirin, 150 mg phenazone)
Trial: 26323054
Drug: manual-guided cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: manual-guided cognitive behavioral therapy (CBT) for insomnia
Trial: 10065089
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy with 5-FU + FA
Trial: 25145487
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1,200 mg/day)
Trial: 27761741
Drug: multisite treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multisite treatment of bifrontal tDCS before bilateral auditory cortex tRNS
Trial: 17828086
Drug: Sinuforte monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinuforte monotherapy in a single daily dose for 7 days
Trial: 27711089
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of serenoa repens, selenium and lycopene extract + bromelain and methylsulfonylmethane extract with levofloxacin 500 mg o.d. for 14 days (Group A)
Trial: 12431356
Drug: DTPw-HB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPw-HB vaccine alone
Trial: 12431356
Drug: DTPw-HB/Hib pentavalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPw-HB/Hib pentavalent vaccine
Trial: 12431356
Drug: DTPw/Hib vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPw/Hib vaccine
Trial: 9867443
Drug: GIK (glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK (glucose, insulin, and potassium infusion)
Trial: 7872278
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg t.i.d. azithromycin, tetracycline 500 mg q.i.d., bismuth subsalicylate 2 tablets q.i.d.
Trial: 113370
Drug: Cream containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream containing 5‐chloro‐8‐hydroxyquinoline, gentamycin and fluprednyliden‐21‐acetate
Trial: 29397376
Drug: semaglutide 0·5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide 0·5 mg
Trial: 29397376
Drug: dulaglutide 1·5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dulaglutide 1·5 mg
Trial: 29397376
Drug: dulaglutide 0·75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dulaglutide 0·75 mg
Trial: 29397376
Drug: semaglutide 1·0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide 1·0 mg
Trial: 22266175
Drug: 1mg oral
RxNorm normalized name: AXITINIB 1MG ORAL TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg oral 17‐β estradiol
Trial: 12478899
Drug: L-OHP plus
RxNorm normalized name: L-OHP
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-OHP plus HCPT
Trial: 1112230
Drug: High-titre rubella
RxNorm normalized name: rubella virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-titre rubella immunoglobulin administered intramuscularly (20 ml)
Trial: 31792258
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PEG‐LG) 40 mg/m2 plus cyclophosphamide (CPM) 600 mg/m2 followed by docetaxel (DTX) 85 mg/m2, administered in four cycles on a 21-day schedule.
Trial: 22542122
Drug: fesoterodine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fesoterodine therapy (4-8 mg daily)
Trial: 17993029
Drug: 18% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18% carbamide peroxide whitening gel
Trial: 15679130
Drug: fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fentanyl 2 microg/kg and etomidate 0.3 mg/kg
Trial: 12032266
Drug: Combination regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimen (colestipol 5 g/d with pravastatin 10 mg/d)
Trial: 12032266
Drug: Conventional regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional regimen (colestipol 10 g/d)
Trial: 9650540
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine therapy at 11 mg/day
Trial: 9650540
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine therapy at 22 mg/day
Trial: 9650540
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine therapy at 44 mg/day
Trial: 2716711
Drug: Jatrox (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jatrox (three times 2 tablets one hour before meals)
Trial: 29908682
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g Melissa officinalis (MO) supplement daily for 8 weeks
Trial: 26855550
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia with 0.5 mg/mL morphine
Trial: 22634446
Drug: 5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 µg or 25 µg VLP immunotherapy
Trial: 22634446
Drug: 1 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 µg VLP immunotherapy
Trial: 22634446
Drug: Placebo immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo immunotherapy (0.9% NaCl)
Trial: 15882248
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during H. pylori eradication and for 3 weeks following treatment.
Trial: 26210512
Drug: Probiotic therapy
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic therapy
Trial: 8834888
Drug: Rufloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufloxacin (400 mg, single dose)
Trial: 19670810
Drug: Norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (400 mg twice a day for 3 days)
Trial: 1557681
Drug: Family intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Family intervention combined with individual treatment
Trial: 1557681
Drug: Individual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatment alone
Trial: 3891615
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (n = 10) with maintained urinary sodium excretion at predieting level
Trial: 27050325
Drug: Prehabilitation (one-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehabilitation (one-hour twice-weekly sessions for at least three and a maximum of four weeks prior to surgery)
Trial: 19903661
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg o.d. and Candesartan 16 mg o.d. (combined treatment)
Trial: 8738773
Drug: Lithium heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium heparin containers
Trial: 1879192
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg b.i.d. for 7 consecutive days
Trial: 1879192
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg b.i.d. for 3 consecutive days
Trial: 7104133
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 10 ml
Trial: 28359862
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg intravenous bolus)
Trial: 21940091
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with epinephrine (12.5 μg/mL)
Trial: 18602820
Drug: Isoflavone tablets
RxNorm normalized name: Soy isoflavones
DrugBank: Isoflavone (DB12007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone tablets at 144 mg/day
Trial: 18602820
Drug: Isoflavone tablets
RxNorm normalized name: Soy isoflavones
DrugBank: Isoflavone (DB12007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone tablets at 288 mg/day
Trial: 18602820
Drug: Soy foods
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy foods providing 96 mg isoflavones/day
Trial: 20619624
Drug: Ciclesonide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide (all doses)
Trial: 1514166
Drug: Combined low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined low dose aspirin (75 mg) and low intensity anticoagulation (INR 1.5)
Trial: 1514166
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin alone (A)
Trial: 1514166
Drug: Double placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double placebo treatment (P)
Trial: 1514166
Drug: Combined low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined low dose aspirin and low intensity anticoagulation (WA)
Trial: 6504946
Drug: Hydroxychloroquine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (600 mg to 1400 mg)
Trial: 18036981
Drug: Standard analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard analgesic care plus immersive VR distraction
Trial: 18036981
Drug: Standard analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard analgesic care
Trial: 15452689
Drug: Pamidronate (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (acute intravenous administration within 10 days of burn injury and again 1 week later)
Trial: 9408071
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg b.i.d. (n = 10)
Trial: 9408071
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg b.i.d. (n = 10)
Trial: 8010581
Drug: Perioperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative administration of antibiotics
Trial: 8010581
Drug: Prolonged perioperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged perioperative administration of antibiotics into the postoperative period
Trial: 27441418
Drug: Featback with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Featback with low-intensity therapist support (weekly)
Trial: 22902987
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg DAS infusion
Trial: 22902987
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg DAS infusion
Trial: 22902987
Drug: 320 mg
RxNorm normalized name: aspirin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg DAS infusion
Trial: 22902987
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of DAS infusion
Trial: 20406154
Drug: Walking to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walking to school daily
Trial: 12681875
Drug: Alendronate 35
RxNorm normalized name: ALENDRONATE 35MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 35 mg once weekly
Trial: 10999794
Drug: Alendronate 5
RxNorm normalized name: ALENDRONATE 5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 5 mg daily
Trial: 10872646
Drug: Amiodarone dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone dosing regimen of 1600 mg/d for 2 days, 1200 mg/d for 5 days, 1000 mg/d for 7 days, 800 mg/d for 7 days, 600 mg/d for 7 days, and 400 mg/d for 62 days followed by a maintenance dose of 343 mg/d (400 mg/d for 6 of 7 days)